Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01225562 · ClinicalTrials.gov registry record · Phase 3
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
A Phase 3 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 3
- Development phase
- 21,379
- Enrollment target
NCT01225562: Completed Phase 3 study, sponsored by AstraZeneca.
NCT01225562 is a Phase 3 study that has completed, run by AstraZeneca. The registered enrollment target is 21,379 participants, above the 771-participant average among 15,282 other Phase 3 trials with a reported enrollment target (2673% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01225562, a Phase 3 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 21,379 participants
- Enrollment target
Study Summary
This study is being carried out to see if a new drug called ticagrelor given twice daily in addition to the ASA therapy decreases the frequency of cardiovascular events (e.g., death from heart disease, heart attack, or stroke).
Primary Outcome
Participants with CV death, MI or Stroke. If no event, censoring occurs at the earliest of the efficacy cut-off date 14 Sep 2014, withdrawal of consent, non-CV death or at the last time point of complete clinical event assessment. Events were adjudicated by a blinded endpoint committee. The Kaplan-Meier estimate reports the percentage of patients who experienced CV Death, MI or stroke within 3 years from randomization
Interventions
- DRUG Ticagrelor 90 mg
- DRUG Ticagrelor 60 mg
- DRUG Ticagrelor Placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21,379 participants |
| Start Date | 2010-10 |
| Est. Completion | 2014-12 |
| Phase | Phase 3 |
What the finished NCT01225562 record still lists
NCT01225562 is an interventional study that assigns participants to a tested intervention. Its 21,379 participants enrollment target places it among the larger protocols in the corpus, above the 771-participant average among 15,282 other Phase 3 trials with a reported enrollment target (2673% higher).
The record links to 0 conditions, and to 3 interventions - of which Ticagrelor 90 mg is the first listed.
NCT01225562 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01225562 about?
NCT01225562 is a clinical study titled "Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin". This study is being carried out to see if a new drug called ticagrelor given twice daily in addition to the ASA therapy decreases the frequency of cardiovascular events (e.g., death from heart disease, heart attack, or stroke).
What is the current status of trial NCT01225562?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 21,379 participants. The study started on 2010-10. Estimated completion is 2014-12.
What interventions are being tested in trial NCT01225562?
The interventions under investigation include: Ticagrelor 90 mg (DRUG), Ticagrelor 60 mg (DRUG), Ticagrelor Placebo (DRUG).
Who is sponsoring clinical trial NCT01225562?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01225562's enrollment target sits among peer trials
21,379 9th of 2000 higher than 1,992 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06047041 · 21,350 participants · NA
Implementation Supports for Improving Identification and Delivery of School-based Mental Health Supports for Middle Schools Students
- NCT07213531 · 21,000 participants
Enhanced Valves Interventions and Safe AI Generated End Results
- NCT05832307 · 22,000 participants · NA
The INFLUENTIAL Trial- Evaluation of National Inpatient Influenza Vaccination Program
- NCT05488080 · 22,032 participants · NA
PAINED: Project Addressing INequities in the Emergency Department
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia